Literature DB >> 17978857

Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation.

Hussein A Sheashaa1, Ahmed F Hamdy, Mohamed A Bakr, Sherif F Abdelbaset, Mohamed A Ghoneim.   

Abstract

BACKGROUND/AIMS: The long-term evaluation of single bolus high dose antithymocyte globulin (ATG) induction therapy has not been adequately studied. We aimed to evaluate its long-term effects in the living related donor kidney transplantation.
METHODS: Eighty adult recipients with their first kidney allograft were randomized into two equal treatment groups, one group received intraoperative single bolus rabbit ATG in a dose of 9 mg/kg and the second group served as a control. All patients were maintained on triple immunosuppressive therapy (steroids, calcineurin inhibitor and antiproliferative agent). We followed them thoroughly for minimum of 5 years.
RESULTS: ATG significantly reduced the proportion of patients who experienced acute rejection episodes in the first year (9/40) when compared to the control group (26/40) and in 5 years (11/40) when compared to (30/40) in controls. The cumulative steroid dose used throughout the study was significantly lower in the ATG group. The overall incidence of posttransplant complications was comparable among the two treatment groups. There was no significant difference in patient and graft survival: 5 year survival was 100% and 85% for the ATG group, and 95% and 92.5% in the control group, respectively.
CONCLUSION: Although routine single bolus ATG induction significantly reduces the incidence of acute rejection, its long-term beneficial effects on graft function and patient and graft survival are not evident.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17978857     DOI: 10.1007/s11255-007-9242-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation--preliminary results.

Authors:  R Samsel; A Chmura; Z Włodarczyk; J Wyzgał; T Cieciura; B Lagiewska; J Pliszczyński; G Korczak; T Lazowski; L Paczek; J Wałaszewski; M Lao; W Rowiński
Journal:  Ann Transplant       Date:  1999       Impact factor: 1.530

2.  Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation--a prospective, randomized study.

Authors:  A Yussim; Z Shapira
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

3.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.

Authors:  D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

4.  Observations on quadruple immunosuppression maintenance therapy using rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following ATG induction.

Authors:  R B Khauli; A Houjaij; S Sawah; Y El-Hout; W Medawwar; M Hussein; A Habbal; M Daouk; M Uwaydah; H Maacaron; A Abdelnoor
Journal:  Transplant Proc       Date:  2005-09       Impact factor: 1.066

5.  Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival.

Authors:  J Kaden; G May; P Müller; J Groth; V Strobelt; E Eger; L Wohlfahrt
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

6.  Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.

Authors:  H Sollinger; B Kaplan; M D Pescovitz; B Philosophe; A Roza; K Brayman; K Somberg
Journal:  Transplantation       Date:  2001-12-27       Impact factor: 4.939

7.  The Banff 97 working classification of renal allograft pathology.

Authors:  L C Racusen; K Solez; R B Colvin; S M Bonsib; M C Castro; T Cavallo; B P Croker; A J Demetris; C B Drachenberg; A B Fogo; P Furness; L W Gaber; I W Gibson; D Glotz; J C Goldberg; J Grande; P F Halloran; H E Hansen; B Hartley; P J Hayry; C M Hill; E O Hoffman; L G Hunsicker; A S Lindblad; Y Yamaguchi
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

8.  Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation.

Authors:  Maroun M Abou-Jaoude; Wassim Y Almawi
Journal:  Mol Immunol       Date:  2003-07       Impact factor: 4.407

9.  A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.

Authors:  H A Bock; H Gallati; R M Zürcher; M Bachofen; M J Mihatsch; J Landmann; G Thiel
Journal:  Transplantation       Date:  1995-03-27       Impact factor: 4.939

10.  A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.

Authors:  William C Goggins; Manuel A Pascual; John A Powelson; Colm Magee; Nina Tolkoff-Rubin; Mary Lin Farrell; Dicken S C Ko; Winfred W Williams; Anil Chandraker; Francis L Delmonico; Hugh Auchincloss; A Benedict Cosimi
Journal:  Transplantation       Date:  2003-09-15       Impact factor: 4.939

View more
  2 in total

1.  Perioperative blood usage and therapeutic plasma exchange in kidney transplantation during a 16-year period in South Korea.

Authors:  Banseok Kim; Minjin Kang; Jae Kwang Lee; Hyung Soon Lee; Yongjung Park
Journal:  Blood Transfus       Date:  2020-06-10       Impact factor: 3.443

2.  Thymoglobulin vs. ATG-Fresenius as Induction Therapy in Kidney Transplantation: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Turun Song; Saifu Yin; Xingxing Li; Yamei Jiang; Tao Lin
Journal:  Front Immunol       Date:  2020-04-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.